Invicro Scientists Published in Science Translational Medicine
Invicro LLC, a Konica Minolta company and a leading provider of imaging biomarkers, core lab services and software for research and drug development, announces that the paper “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury1” has been published in Science Translational Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190904005895/en/
Invicro scientists published in Science Translational Medicine (Graphic: Business Wire)
Invicro London scientists, Doctors Alex Whittington, Jan Passchier and Roger Gunn, are co-authors of this revolutionary study that uses positron emission tomography (PET) to understand tau pathology in traumatic brain injuries (TBI), years after they occur. The results illustrate that tau PET is an encouraging approach for measurement of progressive neurodegeneration associated with tauopathy following TBI.
“It was exciting to be part of this groundbreaking study with Dr. Nikos Gorgoraptis and Prof. David Sharp which shows that Tau PET imaging is an important biomarker for TBI and CTE,” stated Dr. Roger Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular NeuroImaging at Imperial College London. “The advanced Tau analytics that were developed as part of this work further complement Invicro’s leading TauIQ analytics platform in Neurodegeneration.”
TBI can lead to life-long chronic neurodegeneration, including the possibility of dementia. The publication examines how the use of Flortaucipir ([18F]AV-1451, [18F]T807), a PET radioligand for tau, enables the examination of tau pathology in vivo in subjects who are long-term survivors of brain injuries. Flortaucipir has demonstrated potent and specific non-displaceable binding to tau neurofibrillary tangles in both post-mortem human brain tissue and brain scans of subjects with Alzheimer Disease. This study elegantly shows how tau signals can now also be detected in subjects suffering from brain injuries.
“Advanced analytical methods were required to produce these exciting findings and we are delighted that this work has been recognized by Science Translational Medicine, a journal that is known for publishing impactful and high-quality research,” stated Dr. Alex Whittington, PET and MRI Neuro-Imaging Analyst for Invicro.
Established in October 2009 by American Association for The Advancement of Science, Science Translational Medicine is a weekly journal focused on translational medicine and clinical research on human diseases. The journal seeks research that demonstrate significant and innovative progress toward the prevention, diagnosis, or treatment of disease in the field of translational medicine. Science Translational Medicine published “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury” on 4 September 2019 at 2 P.M. EST.
“Tau Imaging in neurodegenerative diseases, specifically TBI, is making significant strides,” stated Dr. Jan Passchier, EVP Global Head Laboratories and Clinics for Invicro. “The success of the research presented in this paper is undoubtedly a result of the combination of academic excellence of our esteemed collaborators and the operational and scientific strength Invicro has been able to bring to bear. I look forward to continuing our joint efforts in this important area in order to support disease understanding and enable development and objective testing of potential therapeutic strategies.”
1. “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury," Authors: Nikos Gorgoraptis, Lucia M. Li, Alex Whittington, Karl A. Zimmerman, Linda M. Maclean, Claire McLeod, Ewan Ross, Amanda Heslegrave, Henrik Zetterberg, Jan Passchier, Paul M. Matthews, Roger N. Gunn, Tom M. McMillan, David J. Sharp
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now as part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the pre-clinical to late-phase clinical markets. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
VP, Global Marketing
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Shows Velarray Lidar in Sleek Car Designs at IAA 2019 Conference14.9.2019 19:39:00 CEST | Press release
Velodyne Lidar, Inc. (Hall 8.0, Booth A13) is showcasing the pristine integration of Velarray lidar sensors into consumer vehicles to make currently available, high-end electric vehicles safer at the IAA 2019 Conference. Velodyne has addressed the market need for lidar technology that enables high-level Advanced Driver Assistance Systems (ADAS) for safe navigation and collision avoidance, all within a compact form factor. The lidar is situated behind the vehicle’s windshield for streamlined, flawless integration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190914005023/en/ Can you see the lidar? The Velarray is embedded in a sleek electric car at IAA 2019 (Hall 8.0, Booth A13). (Photo: Velodyne Lidar) Velodyne booth visitors can see how the Velodyne Velarray™ sensors are beautifully integrated into sleek, high-end vehicles, maintaining their aerodynamic design. The Velarray’s small, embeddable form factor is a powerful so
Insurance Leaders and Visa Digitize Claims Payouts for Individuals and Businesses When They Need It Most13.9.2019 14:37:00 CEST | Press release
Emergencies like car collisions or natural disasters come when people least expect them, leaving individuals unprepared to complete insurance forms, confirm claim estimates, and pay repair shop and medical expenses. During these times, quick access to funds is critical. Visa is committed to working with innovative companies in the insurance industry to help turn outdated and time-consuming processes associated with insurance claim payouts into near real-time1 access to payments when individuals, families and businesses need them the most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190913005323/en/ Visa Direct powers real-time insurance payouts, providing people access to their funds when they need it most. (Graphic: Business Wire) “Visa believes that money shouldn’t be a stressor in moments of crisis and waiting on average six to 10 days to access the money from insurance checks, is outdated, frustrating and costly to th
Wipro Positioned as a Leader in the IDC MarketScape for Utilities Customer Experience, Worldwide13.9.2019 12:55:00 CEST | Press release
Wipro Limited (NYSE: WIT) (BSE: 507685) (NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a leader in the IDC MarketScape: Worldwide Professional Services Firms for Utilities Customer Experience 2019 Vendor Assessment (doc #US42713318, July 2019). Wipro has been recognised for key strengths including provider of fast as-a-service implementations of IT systems, for Utilities and cost-effective quality of service delivery models. The study evaluated the Utilities Customer Experience (CX) transformation and digital capabilities of 15 service providers and mapped them based on strategies, capability and market impact related parameters. Key Highlights include- The report notes Wipro’s internal program aimed at comprehensively addressing the challenges faced by utilities. Selected employees are assigned to one of six "domain tribes" — customer services, network operations, new energy servic
Jefferies to Hold Global Relief Day in Support of Hurricane Relief in the Bahamas, Monday, September 1613.9.2019 12:00:00 CEST | Press release
Jefferies confirmed that the firm’s global trading day for Hurricane Dorian relief efforts in the Bahamas will be held on Monday, September 16. Jefferies will offer investors around the world the opportunity to join efforts to assist those affected by the devastation of this event by trading with Jefferies. As previously announced, Jefferies will donate all net trading commissions on Monday, September 16, from U.S., European and Asia equity, fixed income and foreign exchange trading. In addition, Jefferies will donate an additional $1 million itself, and all 3,656 employees worldwide will be given the opportunity to personally donate to the relief effort. These contributions will be allocated to a series of charities with the goal of quickly getting funds to relief efforts directly involved in the rescue and recovery efforts. Rich Handler, Chairman and Chief Executive Officer of Jefferies, and Brian Friedman, Chairman of the Executive Committee, commented: "All of us at Jefferies are d
Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases13.9.2019 10:00:00 CEST | Press release
Knopp Biosciences LLC today reports data demonstrating that compound subgroups from its proprietary library of potassium-channel modulators selectively target Kv7 channel subtypes associated with a wide range of neurological and smooth muscle diseases. The data is being presented at the International Kv7 Channels Symposium 2019 in Naples, Italy. Presentation Title: The Re-emergence of Kv7 Drug Discovery Presenter: Michael Bozik, M.D., CEO, Knopp Biosciences Date & Time: September 13, 4:35 pm CEST Michael Bozik, M.D., Chief Executive Officer of Knopp, will present the data derived from the Company’s proprietary library of more than 3,000 novel compounds directed to modulating the Kv7 channel, which regulates the flow of potassium ions across cell membranes. The data demonstrate that specific subgroups of Kv7 compounds selectively modulate different Kv7 channel subtypes across ranges of channel activation and inhibition, enabling selection of compounds capable of targeting neurological d
PenSam Selects Moody’s Analytics Economic Scenario Generator to Support New Risk Modeling Framework13.9.2019 09:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, announced today that its software has been selected by PenSam, one of Denmark’s leading labor market pension and insurance firms. PenSam will be using the Moody’s Analytics Economic Scenario Generator (ESG) for actuarial liability valuations, risk management, strategic asset allocation, and asset and liability management (ALM). The Moody’s Analytics ESG is an award-winning simulation framework which clients deploy in areas such as actuarial reporting, risk and capital calculation and analysis, and investment and ALM analysis. PenSam will also take advantage of the Moody’s Analytics Automation Module, which allows insurers to streamline their modeling processes by automating model set-up, execution, and validation, in turn reducing production time and cost. “The Danish pensions and insurance market is going through a period of change, with insurance companies across the country reassessing their risk management frameworks a